AstraZeneca Financials
AstraZeneca (AZN) reported $58.7B in revenue for fiscal year 2025, up 8.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AZN is turning growth into cash-rich earnings while running a lean, liability-funded working-capital model.
Between FY2024 and FY2025, receivables and inventory together rose by roughly$3.5B , yet operating cash flow still increased to$14.6B from$11.9B while net income reached$10.2B . Paired with a current ratio below 1.0x and just$1.4B of long-term debt, that suggests liquidity is being created by the business itself rather than by carrying excess cash or borrowing heavily.
From FY2023 to FY2025, revenue rose from
Reinvestment is increasing, with capex rising from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of AstraZeneca's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for AstraZeneca, and counted as zero in the overall score.
AstraZeneca's revenue grew 8.6% year-over-year to $58.7B, a solid pace of expansion. This earns a growth score of 72/100.
AstraZeneca carries a low D/E ratio of 0.03, meaning only $0.03 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.
AstraZeneca's current ratio of 0.94 is below the typical benchmark, resulting in a score of 16/100. This tight liquidity could limit financial flexibility if cash inflows slow.
AstraZeneca converts 20.0% of revenue into free cash flow ($11.8B). This strong cash generation earns a score of 86/100.
Not available for AstraZeneca, and counted as zero in the overall score.
AstraZeneca passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, AstraZeneca generates $1.42 in operating cash flow ($14.6B OCF vs $10.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
AstraZeneca generated $58.7B in revenue in fiscal year 2025. This represents an increase of 8.6% from the prior year.
AstraZeneca reported $10.2B in net income in fiscal year 2025. This represents an increase of 45.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
AstraZeneca generated $11.8B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 18.4% from the prior year.
AstraZeneca held $5.7B in cash against $1.4B in long-term debt as of fiscal year 2025, with $30.6B of liabilities due within a year.
Not reported for fiscal year 2025.
Margins & Returns
AstraZeneca's net profit margin was 17.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.4 percentage points from the prior year.
AstraZeneca's ROE was 21.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
AstraZeneca invested $2.8B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 46.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
AZN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $58.7B+8.6% | $54.1B+18.0% | $45.8B+3.3% | $44.4B+18.5% | $37.4B+40.6% | $26.6B+9.2% | $24.4B+10.4% | $22.1B-1.7% | $22.5B-2.3% | $23.0B-6.9% | $24.7B |
| Interest Expense | $80.0M+31.1% | $61.0M+84.8% | $33.0M+37.5% | $24.0M+9.1% | $22.0M+4.8% | $21.0M-4.5% | $22.0M+101.7% | -$1.3B+8.2% | -$1.4B-5.9% | -$1.3B-28.0% | -$1.0B |
| Income Tax | $2.2B+31.5% | $1.6B+75.9% | $938.0M+218.4% | -$792.0M-108.4% | -$380.0M-149.2% | $772.0M+140.5% | $321.0M+663.2% | -$57.0M+91.1% | -$641.0M-539.0% | $146.0M-39.9% | $243.0M |
| Net Income | $10.2B+45.3% | $7.0B+18.1% | $6.0B+81.0% | $3.3B+2763.5% | $115.0M-96.3% | $3.1B+156.2% | $1.2B-40.1% | $2.0B-28.5% | $2.9B-15.8% | $3.4B+20.5% | $2.8B |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EPS (Diluted).
AZN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $114.1B+9.6% | $104.0B+2.9% | $101.1B+4.8% | $96.5B-8.4% | $105.4B+57.9% | $66.7B+8.7% | $61.4B+1.2% | $60.7B-4.3% | $63.4B+1.3% | $62.5B+4.1% | $60.1B |
| Current Assets | $28.7B+11.2% | $25.8B+3.1% | $25.1B+10.9% | $22.6B-13.9% | $26.2B+34.3% | $19.5B+25.6% | $15.6B-0.2% | $15.6B+18.6% | $13.2B-0.8% | $13.3B-17.1% | $16.0B |
| Cash & Equivalents | $5.7B+4.1% | $5.5B-6.0% | $5.8B-5.3% | $6.2B-2.6% | $6.3B-19.2% | $7.8B+45.9% | $5.4B+11.1% | $4.8B+45.3% | $3.3B-33.8% | $5.0B-19.6% | $6.2B |
| Inventory | $6.6B+24.0% | $5.3B-2.5% | $5.4B+15.4% | $4.7B-47.7% | $9.0B+123.2% | $4.0B+26.0% | $3.2B+10.5% | $2.9B-4.8% | $3.0B+30.0% | $2.3B+8.9% | $2.1B |
| Accounts Receivable | $15.2B+17.0% | $13.0B+7.0% | $12.1B+15.3% | $10.5B+9.1% | $9.6B+37.3% | $7.0B+21.9% | $5.8B+3.4% | $5.6B+11.3% | $5.0B+9.5% | $4.6B-30.9% | $6.6B |
| Goodwill | $21.2B+1.0% | $21.0B+4.9% | $20.0B+1.2% | $19.8B-0.9% | $20.0B+68.8% | $11.8B+1.5% | $11.7B-0.3% | $11.7B-1.0% | $11.8B+1.4% | $11.7B-1.2% | $11.8B |
| Total Liabilities | $65.4B+3.5% | $63.2B+2.0% | $62.0B+4.3% | $59.4B-10.1% | $66.1B+29.3% | $51.1B+9.2% | $46.8B+0.4% | $46.6B-0.2% | $46.7B+1.9% | $45.9B+10.4% | $41.5B |
| Current Liabilities | $30.6B+9.9% | $27.9B-8.8% | $30.5B+16.2% | $26.3B+16.4% | $22.6B+11.3% | $20.3B+12.1% | $18.1B+11.2% | $16.3B-0.6% | $16.4B+7.4% | $15.3B+2.6% | $14.9B |
| Long-Term Debt | $1.4B+27.7% | $1.1B+29.9% | $857.0M+18.2% | $725.0M-3.8% | $754.0M+54.2% | $489.0M+0.4% | $487.0M-97.5% | $19.1B+7.3% | $17.8B | N/A | N/A |
| Total Equity | $48.7B+19.2% | $40.9B+4.4% | $39.2B+5.7% | $37.1B-5.7% | $39.3B+151.2% | $15.6B+7.1% | $14.6B+3.9% | $14.0B-15.6% | $16.6B-0.2% | $16.7B-9.9% | $18.5B |
| Retained Earnings | $11.0B+247.2% | $3.2B+110.4% | $1.5B+361.7% | -$574.0M-133.6% | $1.7B-67.7% | $5.3B+88.4% | $2.8B-50.5% | $5.7B-30.9% | $8.2B+1.0% | $8.1B-31.2% | $11.8B |
AZN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $14.6B+22.9% | $11.9B+14.7% | $10.3B+5.5% | $9.8B+64.5% | $6.0B+24.3% | $4.8B+61.6% | $3.0B+13.4% | $2.6B-26.8% | $3.6B-13.7% | $4.1B+24.7% | $3.3B |
| Capital Expenditures | $2.8B+46.0% | $1.9B+41.4% | $1.4B+24.7% | $1.1B0.0% | $1.1B+13.5% | $961.0M-1.8% | $979.0M-6.1% | $1.0B-21.3% | $1.3B-8.3% | $1.4B+8.9% | $1.3B |
| Free Cash Flow | $11.8B+18.4% | $9.9B+10.6% | $9.0B+3.1% | $8.7B+78.9% | $4.9B+26.9% | $3.8B+92.9% | $2.0B+26.3% | $1.6B-30.1% | $2.3B-16.6% | $2.7B+35.2% | $2.0B |
| Investing Cash Flow | -$6.8B+14.7% | -$8.0B-96.4% | -$4.1B-37.3% | -$3.0B+73.2% | -$11.1B-3780.0% | -$285.0M+56.6% | -$657.0M-168.2% | $963.0M+141.4% | -$2.3B+41.3% | -$4.0B+6.4% | -$4.2B |
| Financing Cash Flow | -$7.5B-88.8% | -$4.0B+39.2% | -$6.6B+3.8% | -$6.8B-287.0% | $3.6B+265.6% | -$2.2B-24.8% | -$1.8B+13.6% | -$2.0B+30.4% | -$2.9B-121.8% | -$1.3B-250.8% | $878.0M |
| Dividends Paid | $5.0B+7.4% | $4.6B+3.3% | $4.5B+2.7% | $4.4B+13.2% | $3.9B+8.0% | $3.6B-0.6% | $3.6B+3.1% | $3.5B-1.0% | $3.5B-1.2% | $3.6B+2.2% | $3.5B |
Not reported in any period shown, so not listed: Share Buybacks.
AZN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 17.4%+4.4pp | 13.0%0.0pp | 13.0%+5.6pp | 7.4%+7.1pp | 0.3%-11.5pp | 11.8%+6.8pp | 5.0%-4.3pp | 9.3%-3.5pp | 12.8%-2.0pp | 14.8%+3.4pp | 11.4% |
| Return on Equity | 21.0%+3.8pp | 17.2%+2.0pp | 15.2%+6.3pp | 8.9%+8.6pp | 0.3%-19.8pp | 20.1%+11.7pp | 8.4%-6.2pp | 14.6%-2.6pp | 17.2%-3.2pp | 20.4%+5.2pp | 15.3% |
| Return on Assets | 9.0%+2.2pp | 6.8%+0.9pp | 5.9%+2.5pp | 3.4%+3.3pp | 0.1%-4.6pp | 4.7%+2.7pp | 2.0%-1.4pp | 3.4%-1.2pp | 4.5%-0.9pp | 5.5%+0.7pp | 4.7% |
| Current Ratio | 0.940.0x | 0.93+0.1x | 0.820.0x | 0.86-0.3x | 1.16+0.2x | 0.96+0.1x | 0.86-0.1x | 0.96+0.2x | 0.80-0.1x | 0.87-0.2x | 1.08 |
| Debt-to-Equity | 0.030.0x | 0.030.0x | 0.020.0x | 0.020.0x | 0.020.0x | 0.030.0x | 0.03-1.3x | 1.36+0.3x | 1.07-1.7x | 2.75+0.5x | 2.24 |
| FCF Margin | 20.0%+1.7pp | 18.4%-1.2pp | 19.6%0.0pp | 19.7%+6.6pp | 13.0%-1.4pp | 14.4%+6.3pp | 8.2%+1.0pp | 7.1%-2.9pp | 10.0%-1.7pp | 11.7%+3.7pp | 8.1% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Note: The current ratio is below 1.0 (0.94), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where AstraZeneca Ranks
Frequently Asked Questions
What is AstraZeneca's annual revenue?
AstraZeneca (AZN) reported $58.7B in total revenue for fiscal year 2025. This represents a 8.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is AstraZeneca's revenue growing?
AstraZeneca (AZN) revenue grew by 8.6% year-over-year, from $54.1B to $58.7B in fiscal year 2025.
Is AstraZeneca profitable?
Yes, AstraZeneca (AZN) reported a net income of $10.2B in fiscal year 2025, with a net profit margin of 17.4%.
How much debt does AstraZeneca have?
As of fiscal year 2025, AstraZeneca (AZN) had $5.7B in cash and equivalents against $1.4B in long-term debt.
What is AstraZeneca's net profit margin?
AstraZeneca (AZN) had a net profit margin of 17.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is AstraZeneca's return on equity (ROE)?
AstraZeneca (AZN) has a return on equity of 21.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is AstraZeneca's free cash flow?
AstraZeneca (AZN) generated $11.8B in free cash flow during fiscal year 2025. This represents a 18.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is AstraZeneca's operating cash flow?
AstraZeneca (AZN) generated $14.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are AstraZeneca's total assets?
AstraZeneca (AZN) had $114.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are AstraZeneca's capital expenditures?
AstraZeneca (AZN) invested $2.8B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is AstraZeneca's current ratio?
AstraZeneca (AZN) had a current ratio of 0.94 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is AstraZeneca's debt-to-equity ratio?
AstraZeneca (AZN) had a debt-to-equity ratio of 0.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is AstraZeneca's return on assets (ROA)?
AstraZeneca (AZN) had a return on assets of 9.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is AstraZeneca's Piotroski F-Score?
AstraZeneca (AZN) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are AstraZeneca's earnings high quality?
AstraZeneca (AZN) has an earnings quality ratio of 1.42x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is AstraZeneca?
AstraZeneca (AZN) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.